Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.53 -3.1%	$8.02	$6.85 ▼ $21.01	$444.38M	-0.08	497,243 shs	221,414 shs
MBX MBX Biosciences	$11.75 -3.6%	$11.80	$4.81 ▼ $27.50	$392.73M	N/A	264,355 shs	273,419 shs
TARA Protara Therapeutics	$3.08 -1.9%	$3.12	$1.60 ▼ $10.48	$118.83M	1.35	800,826 shs	123,405 shs
TRML Tourmaline Bio	$18.48 -0.6%	$17.15	$11.56 ▼ $29.79	$474.66M	2	254,906 shs	120,341 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-3.09%	-2.21%	-7.72%	-4.56%	-59.32%
MBX MBX Biosciences	-3.61%	-9.89%	+14.30%	+54.20%	+1,174,999,900.00%
TARA Protara Therapeutics	-1.91%	+0.98%	+3.36%	-21.03%	+33.91%
TRML Tourmaline Bio	-0.65%	+2.78%	+9.80%	+15.43%	+21.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.943 of 5 stars	3.5	0.0	2.7	1.7	0.6
MBX MBX Biosciences	2.404 of 5 stars	3.5	0.0	2.4	1.7	0.6
TARA Protara Therapeutics	1.4031 of 5 stars	3.6	1.0	1.1	0.0	0.6
TRML Tourmaline Bio	1.995 of 5 stars	3.5	1.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	298.41% Upside
MBX MBX Biosciences	3.00	Buy	$37.57	219.76% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	565.58% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	166.96% Upside

Current Analyst Ratings Breakdown

Latest TARA, TRML, CGEM, and MBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest TARA, TRML, CGEM, and MBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	TRML Tourmaline Bio	-$0.95	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	11.62	11.62
MBX MBX Biosciences	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	18.03	18.03
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
MBX MBX Biosciences	N/A
TARA Protara Therapeutics	38.13%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
MBX MBX Biosciences	52.19%
TARA Protara Therapeutics	8.40%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
TARA Protara Therapeutics	30	38.58 million	35.34 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

TARA, TRML, CGEM, and MBX Headlines

Recent News About These Companies

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Brokerages

July 19 at 2:15 AM | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Shares Down 2.1% - Should You Sell?

July 16 at 4:29 AM | marketbeat.com

Tourmaline Bio Inc News (TRML) - Investing.com

July 3, 2025 | investing.com

TRML - Tourmaline Bio Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

TRML - Tourmaline Bio Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

June 24, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.comT

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 20, 2025 | fiercebiotech.comF

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 20, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.comA

Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 3, 2025 | finanznachrichten.de

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 2, 2025 | globenewswire.com

Tourmaline Bio initiated with a Buy at Chardan

April 23, 2025 | markets.businessinsider.com

Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

April 23, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, TRML, CGEM, and MBX Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.53 -0.24 (-3.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.52 0.00 (-0.07%)

As of 07/18/2025 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

MBX Biosciences NYSE:MBX

$11.75 -0.44 (-3.61%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.73 -0.02 (-0.17%)

As of 07/18/2025 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Protara Therapeutics NASDAQ:TARA

$3.08 -0.06 (-1.91%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.08 0.00 (0.00%)

As of 07/18/2025 05:26 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Tourmaline Bio NASDAQ:TRML

$18.48 -0.12 (-0.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$18.92 +0.45 (+2.41%)

As of 07/18/2025 05:14 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time